Drug General Information |
Drug ID |
D05HQX
|
Former ID |
DNC003874
|
Drug Name |
4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
|
Formula |
C16H17N3O
|
Canonical SMILES |
CCCCC1=C2C(=NC=CN2)NC1=C3C=CC(=O)C=C3
|
InChI |
1S/C16H17N3O/c1-2-3-4-13-14(11-5-7-12(20)8-6-11)19-16-15(13)17-9-10-18-16/h5-10,17H,2-4H2,1H3,(H,18,19)
|
InChIKey |
AYIIQABSVDIZSY-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
G1/S-specific cyclin E1 |
Target Info |
Inhibitor |
[1]
|
Cyclin-A2 |
Target Info |
Inhibitor |
[1]
|
Cell division protein kinase 2 |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Cell cycle
|
Oocyte meiosis
|
p53 signaling pathway
|
PI3K-Akt signaling pathway
|
Hepatitis B
|
Measles
|
Pathways in cancer
|
Viral carcinogenesis
|
MicroRNAs in cancer
|
Prostate cancer
|
Small cell lung cancerhsa03030:DNA replication
|
Base excision repair
|
Nucleotide excision repair
|
Mismatch repair
|
HTLV-I infectionhsa04068:FoxO signaling pathway
|
Progesterone-mediated oocyte maturation
|
Herpes simplex infection
|
Epstein-Barr virus infection
|
Small cell lung cancer
|
NetPath Pathway
|
IL2 Signaling Pathway
|
TCR Signaling PathwayNetPath_11:TCR Signaling Pathway
|
PANTHER Pathway
|
Cell cycle
|
Parkinson disease
|
p53 pathway
|
p53 pathway feedback loops 2P00059:p53 pathway
|
p53 pathway feedback loops 2
|
Pathway Interaction Database
|
Signaling events mediated by PRL
|
E2F transcription factor network
|
mTOR signaling pathway
|
FOXM1 transcription factor network
|
BARD1 signaling events
|
PLK3 signaling events
|
Regulation of retinoblastoma proteinsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
p73 transcription factor network
|
ATR signaling pathway
|
IL2-mediated signaling events
|
FoxO family signaling
|
p53 pathway
|
Regulation of retinoblastoma protein
|
PathWhiz Pathway
|
Nucleotide Excision Repair
|
Reactome
|
E2F mediated regulation of DNA replication
|
G0 and Early G1
|
SCF(Skp2)-mediated degradation of p27/p21
|
DNA Damage/Telomere Stress Induced Senescence
|
Cyclin E associated events during G1/S transition
|
G1/S-Specific Transcription
|
p53-Dependent G1 DNA Damage ResponseR-HSA-113510:E2F mediated regulation of DNA replication
|
Cdc20:Phospho-APC/C mediated degradation of Cyclin A
|
Regulation of APC/C activators between G1/S and early anaphase
|
Senescence-Associated Secretory Phenotype (SASP)
|
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
|
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
|
HDR through Homologous Recombination (HRR)
|
Processing of DNA double-strand break ends
|
Dual Incision in GG-NER
|
Dual incision in TC-NER
|
Gap-filling DNA repair synthesis and ligation in TC-NER
|
G2 Phase
|
Orc1 removal from chromatin
|
Cyclin A/B1 associated events during G2/M transition
|
Cyclin A:Cdk2-associated events at S phase entryR-HSA-1538133:G0 and Early G1
|
Activation of ATR in response to replication stress
|
p53-Dependent G1 DNA Damage Response
|
Cyclin A:Cdk2-associated events at S phase entry
|
Meiotic recombination
|
Factors involved in megakaryocyte development and platelet production
|
WikiPathways
|
DNA Damage Response
|
ID signaling pathway
|
G1 to S cell cycle control
|
Retinoblastoma (RB) in Cancer
|
Integrated Pancreatic Cancer Pathway
|
Parkinsons Disease Pathway
|
Parkin-Ubiquitin Proteasomal System pathway
|
Signaling Pathways in Glioblastoma
|
TSH signaling pathway
|
Mitotic G1-G1/S phases
|
Cell Cycle
|
miRNAs involved in DNA damage response
|
miRNA Regulation of DNA Damage Response
|
Androgen receptor signaling pathwayWP615:Senescence and Autophagy in Cancer
|
Mismatch repair
|
DNA Replication
|
EGF/EGFR Signaling Pathway
|
S Phase
|
Nifedipine Activity
|
Primary Focal Segmental Glomerulosclerosis FSGS
|
Nucleotide Excision Repair
|
Telomere Maintenance
|
Synthesis of DNA
|
Base Excision RepairWP707:DNA Damage Response
|
M/G1 Transition
|
Meiotic Recombination
|
Aryl Hydrocarbon Receptor
|
ATM Signaling Pathway
|
Spinal Cord Injury
|
Oncostatin M Signaling Pathway
|
Prostate Cancer
|
Integrated Breast Cancer Pathway
|
Integrated Cancer pathway
|
Regulation of DNA replication
|
Mitotic G2-G2/M phases
|
Factors involved in megakaryocyte development and platelet production
|
APC/C-mediated degradation of cell cycle proteins
|
Cell Cycle Checkpoints
|
References |
REF 1 | J Med Chem. 2003 Jan 16;46(2):222-36.Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. |